Balance Sheet

Cash Flow Statement

Acquisitions Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Sunshine Biopharma (SBFM) Asset Writedowns and Impairment (2025)

Sunshine Biopharma filings provide 1 years of Asset Writedowns and Impairment readings, the most recent being $131788.0 for Q4 2025.

On a quarterly basis, Asset Writedowns and Impairment changed N/A to $131788.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.7 million, a N/A change, with the full-year FY2025 number at $1.7 million, changed N/A from a year prior.
Asset Writedowns and Impairment hit $131788.0 in Q4 2025 for Sunshine Biopharma, down from $554650.0 in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $1.1 million in Q2 2025 to a low of $131788.0 in Q4 2025.